SVB Wealth’s BridgeBio Pharma BBIO Stock Holding History

SVB Wealth’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-125	Closed	-$4.32K	–	617
2025 Q1	$4.32K	Buy	+125	New	+$4.21K	﹤0.01%	1062

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SVB Wealth's BBIO Position: Q2 2025 in Review

SVB Wealth sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 125 shares — an estimated $4.32K sold.

SVB Wealth first reported a position in BBIO in Q1 2025 and held it in 1 quarter. The position peaked at $4.32K in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

SVB Wealth reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 125 BridgeBio Pharma shares in Q2 2025, an estimated $4.32K.
SVB Wealth first reported a position in BridgeBio Pharma in Q1 2025 and held it in 1 quarter.
SVB Wealth's BridgeBio Pharma position peaked at $4.32K in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.